miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers

Li, Tong; Zhang, Yu; Meng, Yunlong; Bo, Li-shan; Ke, Wenbo

doi:10.1007/s11095-017-2202-7

Cited by 31 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further understand the effect of ATRA on GC, studies have been conducted and three main anti-cancerous effect of this molecule have been identified: (i) inhibition of cell cycle and induction of cell differentiation [ 88 , 89 , 90 , 91 , 92 ]; (ii) pro-apoptotic action [ 88 , 93 , 94 , 95 ], and (iii) inhibition of CSCs properties [ 88 , 96 , 97 ] ( Table 2 ).…”

Section: Atra On Gc Modelsmentioning

confidence: 99%

“…According to Li T et al, a combination of ATRA, Sorafenib, and miRNA in encapsulated nanoparticles inhibit GC cells proliferation and initiate apoptosis in vitro [ 88 ].…”

Section: Atra On Gc Modelsmentioning

confidence: 99%

“…According to Nguyen et al, ATRA inhibits tumorsphere formation and survival in a dose-dependent manner [ 19 ]. It has been demonstrated that ATRA reduces tumor growth in GC PDXs or GC cell lines xenograft models [ 88 , 96 ]. Moreover, it has been shown that there are less mice bearing liver metastasis, after intrasplenic xenograft of GC cells (BGC 823 and MKN45), when they were fed with ATRA rather than with a control treatment (33–50%) [ 97 ].…”

Section: Atra On Gc Modelsmentioning

confidence: 99%

See 2 more Smart Citations

Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review

Bouriez

Giraud

Gronnier

et al. 2018

IJMS

View full text Add to dashboard Cite

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide with a five-year survival rate of around 25%, and 4% when diagnosed at a metastatic stage. Cancer stem cells (CSC) have recently been characterized as being responsible for resistance to radio/chemotherapies and metastasis formation, opening up perspectives for new targeted therapies. Those CSCs express biomarkers such as cluster of differentiation 44 (CD44) and display high aldehyde dehydrogenase activity that converts vitamin A-derived retinal into retinoic acids. All-trans retinoic acid (ATRA), which has pro-differentiating properties, has revolutionized the prognosis of acute promyelotic leukemia by increasing its remission rate from 15% to 85%. Recent studies have started to show that ATRA also has an anti-tumoral role on solid cancers such as GC. The purpose of this review is therefore to summarize the work that evaluated the effects of ATRA in GC and to evaluate whether its anti-cancerous action involves gastric CSCs targeting. It has been demonstrated that ATRA can block the cell cycle, enhance apoptosis, and decrease gastric CSCs properties in GC cell lines, tumorspheres, and patient-derived xenograft mice models. Therefore, retinoids and new synthetic retinoids seem to be a promising step forward in targeted therapy of gastric CSC in combination with existing chemotherapies. Future studies should probably focus on these points.

show abstract

Section: Atra On Gc Modelsmentioning

confidence: 99%

“…According to Li T et al, a combination of ATRA, Sorafenib, and miRNA in encapsulated nanoparticles inhibit GC cells proliferation and initiate apoptosis in vitro [ 88 ].…”

Section: Atra On Gc Modelsmentioning

confidence: 99%

Section: Atra On Gc Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review

Bouriez

Giraud

Gronnier

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Li's team loaded sorafenib (SRF) and all-trans retinoic acid (ATRA) in PEGylated solid lipid nanoparticles (SLNs) composed of Gelucire, and loaded miRNA onto the surface of the SLNs based on the electrostatic interaction. 88 Liu's team employed intelligent gelatinases-stimuli nanoparticles to co-deliver miRNA and docetaxel to inhibit cancer stem cells. 89 Hu's team and Wu's team each introduced PCL-PEG nanoparticles coated with trastuzumab (HER-PEG-PCL NPs) to control the delivery of the inhibitor of miRNA.…”

Section: Synthetic Nanoparticles and Compoundsmentioning

confidence: 99%

<p>Research Progress in microRNA-Based Therapy for Gastric Cancer</p>

Zhao

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic therapy is still an urgent problem to overcome. In the past decade, the essential roles of microRNAs (miRNAs) in tumor treatment have been increasingly recognized. In particular, miRNAs were recently shown to reverse the resistance to chemotherapy drugs such as 5-fluorouracil, cisplatin, and doxorubicin. Synthesized nanoparticles loaded with mimics or inhibitors of miRNAs can directly target tumor cells to suppress their growth. Moreover, exosomes may serve as promising safe carriers for mimics or inhibitors of miRNAs to treat GC. Some miRNAs have also been shown to play roles in the mechanism of action of other anti-tumor drugs. Therefore, in this review, we highlight the research progress on microRNA-based therapy in GC and discuss the challenges and prospects associated with this strategy. We believe that microRNA-based therapy has the potential to offer a clinical benefit to GC patients, and this review would contribute to and motivate further research to promote this field toward this ultimate goal.

show abstract

“…Sorafenib (SRF) is an anticancer drug, which is mainly used in the treatment of gastric cancers. 16 SRF is a tyrosine kinase inhibitor, which inhibits proliferation, angiogenesis, and invasion of tumor cells. SRF has been administered in NP encapsulation and demonstrated better antitumor effect compared with that of free drug counterpart.…”

Section: Introductionmentioning

confidence: 99%

Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity

Yang

Liu

et al. 2018

DDDT

View full text Add to dashboard Cite

PurposeGastric cancer is one of the most common human epithelial malignancies, and using nanoparticles (NPs) in the diagnosis and treatment of cancer has been extensively studied. The aim of this study was to develop hyaluronic acid (HA) containing lipid NPs coloaded with cisplatin (CDDP) and sorafenib (SRF) for the treatment of gastric cancer.Materials and methodsHA and CDDP containing lipid prodrug was synthesized using polyethylene glycol (PEG) as a linker (HA-PEG-CDDP). HA-PEG-CDDP and SRF were entrapped into the lipid NPs by nanoprecipitation method (H-CS-NPs). The physicochemical and biochemical properties such as size, zeta potential, and drug release pattern were studied. In vitro viability was also evaluated with MKN28 and SGC7901 human gastric cancer cells. In vivo testing including biodistribution and accumulation in tumor tissue was applied in gastric tumor-bearing mice to confirm the inhibition of gastric cancer.ResultsH-CS-NP has a particle size of 173.2±5.9 nm, with a zeta potential of −21.5±3.2 mV. At day 21 of in vivo treatment, H-CS-NPs inhibited the tumor volume from 1,532.5±41.3 mm3 to 259.6±16.3 mm3 with no obvious body weight loss. In contrast, mice treated with free drugs had body weight loss from 20 to 15 g at the end of study.ConclusionThe results indicate that H-CS-NPs enhanced the antitumor effect of drugs and reduced the systemic toxicity effects. It could be used as a promising nanomedicine for gastric cancer combination therapy.

show abstract

miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers

Abstract: Overall, unique combination of miRNA coupled with SRF + ATRA in a lipid nanocarrier could be a promising therapeutic approach in gastric cancer treatment.

Cited by 31 publications

References 31 publications

Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review

Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review

<p>Research Progress in microRNA-Based Therapy for Gastric Cancer</p>

Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity

Contact Info

Product

Resources

About